Prevalence and Treatment Efficacy of Genitourinary Mycoplasmas in Women with Overactive Bladder Symptoms by Lee, Young-Suk et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2010 625 Korean J Urol 2010;51:625-630
www.kjurology.org
DOI:10.4111/kju.2010.51.9.625
Voiding Dysfunction
Prevalence and Treatment Efficacy of Genitourinary Mycoplasmas 
in Women with Overactive Bladder Symptoms
Young-Suk Lee, Ji-Yoon Kim
1, Joon Chul Kim
2, Won Hee Park
3, Myung-Soo Choo
1, Kyu-Sung Lee
Department of Urology, Sungkyunkwan University School of Medicine, 
1University of Ulsan College of Medicine, 
2College of Medicine, 
The Catholic University of Korea, Seoul, 
3Inha University College of Medicine, Incheon, Korea
Purpose: To evaluate the incidence of genitourinary mycoplasmas and the efficacy of 
antibiotics in women with overactive bladder (OAB) symptoms. 
Materials and Methods: Women with OAB symptoms (micturition ≥8/24 hours and 
urgency ≥1/24 hours) for ≥3 months were screened for Mycoplasma hominis (M. homi-
nis), Ureaplasma urealyticum (U. urealyticum), and Chlamydia trachomatis (C. tracho-
matis). Specimens from urethral and cervical vaginal swabs were examined for M. hom-
inis and U. urealyticum by using the Mycoplasma IST2 kit and for C. trachomatis by 
using PCR. Women with positive results were treated with a 1 g dose of azithromycin. 
Persistent infection was treated with doxycycline. Changes in a 3-day bladder diary, 
Patient Perception of Bladder Condition (PPBC), and International Consultation on 
Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) 
were evaluated 4 weeks after negative conversion. Patient satisfaction was assessed. 
Results: Of 84 women screened, 42.8% were positive (U. urealyticum, 40.5%; M. homi-
nis, 7.1%; C. trachomatis, 3.6%; two organisms, 8.3%). After treatment, 82.7% obtained 
negative conversion, and their median number of micturition episodes decreased from 
10.6/24 hours to 8.1/24 hours (p=0.002). PPBC and domain scores of the ICIQ-FLUTS 
(filling and quality of life) significantly improved. About 87.5% women with negative 
conversion were satisfied with the treatment. 
Conclusions: Considering diagnostic tests and treatment for genitourinary myco-
plasmas might be beneficial before invasive workup or treatment in women with OAB 
symptoms.
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INTRODUCTION
Overactive bladder (OAB) syndrome is described as “ur-
gency, with or without urgency incontinence, usually with 
frequency and nocturia” by the International Continence 
Society (ICS) Terminology Committee [1]. However, a vari-
ety of medical conditions share the symptoms of OAB, so 
it is important to rule out these causes. Thus, the ICS 
Terminology Committee stated that the term OAB can be 
used only if there is no proven infection or other obvious 
pathology [1].
Urinary tract infection (UTI) is the most common con-
dition that can cause OAB symptoms. The isolation of caus-
ative organisms through urine culture plays a crucial role 
in the diagnosis of UTI. However, even if ordinary bacteria 
are not cultured, there is some evidence to suggest that 
atypical organisms, such as mycoplasmas, may be asso-
ciated with OAB symptoms [2-4].
Mycoplasmas are the simplest microorganisms and lack 
a cell wall, a feature largely responsible for their lack of a 
reaction to gram stain and their lack of susceptibility to 
drugs such as penicillin that interfere with cell wall syn-Korean J Urol 2010;51:625-630
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thesis [5]. Although scientists have isolated at least 17 spe-
cies of mycoplasmas from humans, four types are respon-
sible for clinically significant infections. These species are 
Mycoplasma pneumoniae, Mycoplasma hominis (M. homi-
nis), Mycoplasma genitalium, and Ureaplasma species. 
These were generally viewed as commensals, although 
they usually manifest a predilection for particular host tis-
sues, such as urogenital or respiratory tracts [6]. However, 
it is now being recognized that these organisms play a more 
important role in human infections than was previously 
thought. Their slow-growing, non-culturable nature en-
ables them to establish chronic infections, resist the effects 
of antibiotics, and protect the organisms against immune 
system reactivity [7]. Accordingly, for patients presenting 
with chronic irritative urinary symptoms, especially those 
for whom ordinary cultures are negative, further tests can 
be indicated specifically for mycoplasmas.
Herein, we conducted a prospective study to estimate the 
incidence of genitourinary mycoplasma infections and to 
evaluate the efficacy of antibiotic treatment for these or-
ganisms in women with OAB symptoms.
MATERIALS AND METHODS
This was a multicenter, prospective, single-arm study. The 
institutional review boards of the 4 study centers approved 
this study. Written informed consent was obtained from all 
participants.
1. Participants
Women with OAB symptoms for at least 3 months were 
screened. Inclusion criteria were women aged ≥20 and ≤
80 years with micturition episodes ≥8/24 hours and ur-
gency episodes ≥1/24 hours on a 3-day bladder diary. 
Urgency episodes were defined as the number of mictur-
ition episodes associated with a Urinary Sensation Scale 
rating ≥3 [8]. Exclusion criteria were a positive urine cul-
ture for bacteria using Gram stain, postvoid residual ≥150 
ml, history of pelvic irradiation, neuropathic bladder, and 
evidence of chronic inflammation such as interstitial 
cystitis. Women who were pregnant or who had child-
bearing potential and did not use a reliable method of birth 
control during the study period were excluded. Patients 
who required concomitant administration of the following 
drugs or treatment modalities were also excluded: an-
ti-cholinergics, alpha-blockers, tricyclic antidepressants, 
selective serotonin reuptake inhibitors, electrical or elec-
tromagnetic stimulation, and neuromodulation. 
2. Evaluation 
At the baseline visit, all participants were evaluated for 
their medical history, underwent a physical examination 
including pelvic examination, and completed the Patient’s 
Perception of Bladder Condition (PPBC) [9] and Interna-
tional Consultation on Incontinence Questionnaire-Female 
Lower Urinary Tract Symptoms (ICIQ-FLUTS) [10]. Also, 
urethral and cervical vaginal swabs were obtained from all 
participants. The Mycoplasma IST2 kit (BioMerieux, Inc., 
Marcy-I’Etoile, France) was used for the culture, identi-
fication, and antibiotics susceptibility test for M. hominis 
and Ureaplasma urealyticum (U. urealyticum) [11]. Colony 
forming units ≥10
4/ml were regarded as a positive result 
for M. hominis and U. urealyticum infection. For the de-
tection of Chlamydia trachomatis (C. trachomatis), poly-
merase chain reaction (PCR) was used, and a positive re-
sult was regarded as infection.
Four weeks after negative conversion, patients were 
evaluated by use of a 3-day bladder diary, the PPBC, the 
ICIQ-FLUTS, and Patient Perception of Treatment 
Benefit Questionnaire (PPTB) [12]. Primary endpoints 
were the percentage of positive cultures for M. hominis, U. 
urealyticum, and C. trachomatis, and the change in the 
number of micturition episodes after negative conversion. 
Secondary endpoints were the changes in the number of ur-
gency episodes and changes on the PPBC, ICIQ-FLUTS, 
and PPTB. For patients with persistent infection after 
treatment, the bladder diary, PPBC, ICIQ-FLUTS, and 
PPTB were assessed 4 weeks after treatment.
3. Treatment
Women with a positive result were initially treated with 
a 1 g dose of azithromycin. Two weeks after treatment, fol-
low-up swab samples were taken from the previously pos-
itive site, either the urethra or the cervical vagina. Patients 
who had obtained negative conversion underwent no fur-
ther treatment, whereas those with persistent infection 
were re-treated with 100 mg of doxycycline twice daily for 
7 days, followed by additional swabs 2 weeks after the 
treatment. Identical treatment was given to the patients’ 
sexual partners, and condom usage was recommended dur-
ing the study period. 
4. Sample size determination
Potts et al showed that the difference in the mean number 
of micturition episodes was about −2.0/24 hours with a 
standard deviation of 3.5 after treatment of mycoplasmas 
in women with chronic urinary symptoms [2]. With a 0.05 
significance level and 80% power to detect a difference in 
the number of micturition episodes of −2.0/24 hours, a 
sample size of 27 patients was needed to be positive for 
infection. Assuming a dropout rate of 20% and an incidence 
of mycoplasma infections in OAB patients of 20%, 160 wom-
en with OAB symptoms were scheduled to be screened.
5. Statistical analysis
Statistical analysis was performed by using the SPSS 17.0 
(SPSS, Chicago, IL, USA) program for Windows
Ⓡ (Microsoft 
Corporation, Seattle, WA, USA). Wilcoxon signed rank test 
was used to compare nonparametric continuous variables. 
For all analyses, p＜0.05 was considered statistically 
significant.Korean J Urol 2010;51:625-630
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TABLE 1. Baseline characteristics of women positive for Myco-
plasma hominis, Ureaplasma urealyticum and Chlamydia tra-
chomatis (n=29)
Characteristics Values
Age (years) (range)      51 (38-71)
Duration of symptom (months) (range)      12 (3-360)
Marital status (n, %)
    Single  1 (3)
    Married  25 (86)
    Widowed  2 (7)
    Divorced  1 (3)
Previous OAB medication (n, %)
    Yes    5 (17)
    No  24 (83)
Frequency/24 hours (median, range)       10.0 (8.0-19.3) 
Urgency episode/24 hours (median, range)         2.7 (1.0-17.0)
ICIQ-FLUTS (median, range)
    Filling sum         7.0 (3.0-17.0)
    Voiding sum         2.0 (0.0-14.0)
    Incontinence sum         3.0 (0.0-20.0)
    Sexual function sum       0.0 (0.0-4.0)
    Quality of life sum         6.0 (0.0-14.0)
PPBC (median, range)       4.0 (3.0-6.0)
OAB: overactive bladder, ICIQ-FLUTS: International Consulta-
tion on Incontinence Questionnaire-Female Lower Urinary Tract
Symptoms, PPBC: Patient’s Perception of Bladder Condition
FIG. 1. Participant flow (n=84). 
a: iden-
tical treatment for the women’s sexual
partners, condom use during study pe-
riod, 
b: after 2 weeks of treatment, from 
the previous infected site either urethra
and/or cervical vagina. PCR: polyme-
rase chain reaction.
RESULTS
Of a total of 84 women screened, 42.8% (36/84) were found 
to be positive: 40.5% (34/84) for U. urealyticum, 7.1% (6/84) 
for M. hominis, and 3.6% (3/84) for C. trachomatis. About 
8.3% (7/84) of women had 2 organisms: 7.1% (6/84) were 
positive for U. urealyticum and M. hominis and 1.2% (1/84) 
were positive for U. urealyticum and C. trachomatis. Overall, 
7 of the 36 positive women were excluded: 5 because of hav-
ing taken anti-cholinergics and 2 because of being lost to 
follow-up. Fig. 1 shows the participant flow. The demo-
graphic data and baseline characteristics of the 29 women 
are summarized in the Table 1. After treatment with anti-
biotics, 24 of 29 (82.7%) patients obtained negative con-
version: 14 (48.3%) after the first treatment with azithro-
mycin and 10 (34.5%) after the second treatment with 
doxycycline.
Among 24 women with negative conversion, the median 
number of micturition episodes per 24 hours was reduced 
from 10.6 (range, 8.0-19.3) to 8.1 (range, 4.0-20.7) (p=0.002). 
The median number of urgency episodes per 24 hours was 
reduced from 2.7 (range, 10.0-17.0) to 0.3 (range, 0-20.7) 
(p=0.097). In terms of PPBC, the median score was im-
proved from 4.0 (range, 3.0-6.0) to 2.0 (range, 1.0-6.0) 
(p=0.001), and the scores for 58.3% (14/24) of the women 
were improved by at least 2 points. In terms of the ICIQ- 
FLUTS, the filling and quality of life domain scores im-
proved significantly (Fig. 2). Twenty-one of 24 (87.5%) pa-
tients reported to have benefitted from the treatment and 
9 (37.5%) of them reported “much benefit”. Also 21 of 24 Korean J Urol 2010;51:625-630
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FIG. 2. Changes in International Consultation on Incontinence
Questionnaire-Female Lower Urinary Tract Symptoms after 
obtaining negative conversion (n=24). FS: filling sum, VS: voiding
sum, IS: incontinence sum, Sex: sexual function, QoL: quality of 
life. 
(87.5%) reported that they were satisfied with the treat-
ment and 8 (33.3%) of them reported that they were “very 
satisfied”.
For the 5 women with persistent infection after antibiotic 
treatment, the median number of micturition episodes per 
24 hours was reduced from 9.3 (range, 8.0-14.3) to 8.3 
(range, 6.0-15.0) (p=0.269), and the median number of ur-
gency episodes was reduced from 3.3 (range, 1.0-9.3) to 0.0 
(range, 0.0-8.0) (p=0.080). Changes on the PPBC and 
ICIQ-FLUTS were not statistically significant. Four of the 
five (80%) women reported having benefitted and one (20%) 
of them reported “much benefit” from the treatment. Four 
of five (80%) reported that they were satisfied with the 
treatment and none of them reported that they were “very 
satisfied”.
DISCUSSION
Mycoplasma infection became a subject of interest in the 
early 1980s for its association with premature rupture of 
membranes, premature labor, endometritis, stillbirth, and 
neonatal respiratory distress syndrome. Several studies 
have attempted to implicate mycoplasma infection as a 
cause of chronic urinary symptoms [2-4]. Our results dem-
onstrated that 42.8% of women with OAB symptoms were 
positive for mycoplasma and chlamydia infections. 
The reported prevalence rates of mycoplasma infections 
are various. The wide ranges are due to differences in the 
method of isolation (e.g., culture, serological assay, PCR, 
antigen detection enzyme-linked immunoabsorbant as-
say), method of sample collection (e.g., urine, cervical/vagi-
nal swab, vaginal discharge), geographical and economical 
factors, and social and sexual habits. Wave III of the 
National Longitudinal Study of Adolescent Health tested 
14,322 young men and women for mycoplasma infection 
with urine specimens [13]. The prevalences of Mycoplasma 
genitalium (M. genitalium) and chlamydia were 1.0% and 
4.2%, respectively. The prevalence was 11 times higher 
among respondents who reported living with a sexual part-
ner, and increased by 10% for each additional sexual 
partner. Also, the prevalence was 7 times higher among 
Blacks [13]. On the contrary, a community-based study repo-
rted an extremely high rate of mycoplasma infection (＞70% 
for M. hominis and ＞78% for U. urealyticum) in Papua New 
Guinea [14]. These rates are among the highest ever 
reported. The authors explained that both low socio-
economic status and experience with multiple sexual part-
ners were associated with the high rates.
According to a retrospective comparative analysis of vag-
inal and endocervical cultures from 27,172 women visiting 
a genital tract diseases clinic, M. hominis was positive in 
0.1% of symptomatic and 0.05% of asymptomatic women 
of childbearing age [15]. U. urealyticum was positive in 
10.9% and 10.7%, respectively. This study reported that 
hormonal contraception and consistent condom use were 
protective factors for mycoplasma infections. In Central/ 
West and North Africa, no steady partners, more than 1 
partner in the previous 6 months, and intrauterine devices 
were risk factors. The presence of symptoms was not sig-
nificantly related to the mycoplasma infections [15]. On the 
other hand, another study showed different prevalence 
rates according to the presence of symptoms [16]. Among 
symptomatic women in a sexually transmitted disease 
clinic, M. genitalium and C. trachomatis were positive in 
6% (26/461) and 10% (45/465). However, the prevalence 
was 2% (1/59) and 0%, respectively, among women at a can-
cer screening center [16]. A Japanese study also showed 
6.8% (8/117) of women with genital symptoms were pos-
itive for mycoplasma infections, compared with none of 80 
women without symptoms [17]. Putting those various re-
ports together, mycoplasmas have been isolated in up to 
10% of women with genitourinary symptoms.
Our prevalence rate was higher than those reported in 
the above studies, but is similar to that of Potts et al who 
reported that 48% (23/48) of women with chronic urinary 
symptoms were positive for mycoplasmas (1 for M. homi-
nis, 22 for U. urealyticum), although the inclusion criteria 
and the detection method differed from ours [2]. A recent 
study also revealed high prevalence rates of mycoplasma 
infections using the Mycoplasma IST2 kit, which was the 
same method that we used [4]. They reported that about 
53% (81/153) of women with chronic voiding symptoms 
were positive for mycoplasmas (5 for M. hominis, 81 for U. 
urealyticum). The individual infection rate of M. hominis 
and U. urealyticum was 7.1% and 40.5%, respectively, in 
our study. M. hominis infection was always associated with 
U. urealyticum infection. In the latter study [4], M. hominis 
was also always detected in association with with U. 
urealyticum. High rates of co-infection of M. hominis with 
U. urealyticum were also reported in the above-mentioned 
prevalence studies. This can be explained by the fact that 
M. hominis and U. urealyticum are important opportun-
istic pathogens in the genitourinary tract.
After antimicrobial treatment, 24 of 29 (82.8%) infected Korean J Urol 2010;51:625-630
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women obtained negative conversion. For the 5 women with 
persistent infection, susceptible antibiotics were given on 
the basis of the result of a follow-up test after the last assess-
ment. Four weeks after negative conversion, micturition 
frequency and scores on the symptom questionnaires were 
significantly improved, and the patient perception of treat-
ment benefit and satisfaction was high. In other studies, 
micturition frequency and symptom severity were also im-
proved after antimicrobial therapies [2,4]. However, we 
failed to prove significant improvement in urgency episodes 
and some domain scores of the ICIQ-FLUTS questionnaire. 
This might be due to the difference in patient characteristics. 
The other studies included women with a history of pre-
vious treatment for their symptoms. However, most of our 
patients (83%) had no history of treatment. Therefore, our 
patients might have had milder symptoms than in other 
studies. Apart from the patient characteristics, we used a 
voiding diary for quantitative assessment of urgency epi-
sodes and standardized questionnaires, which differed 
from the other studies, in which a symptom severity score 
was applied, with 0 points indicating mild or no symptoms 
and 3 points indicating severe symptoms. These might also 
be why the improvement in urgency episodes and some do-
main scores on the questionnaire was not significant.
Another study also suggested that urinary symptoms 
may be associated with unrecognized mycoplasma infection. 
Burkhard et al evaluated the efficacy of antimicrobial 
treatment (doxycycline) for urinary urgency, frequency, 
and chronic urethral and pelvic pain in women [3]. After 
treatment, 71% of the women became symptom-free or had 
a subjective decrease in symptoms [3]. Although causative 
organisms were not identified in most cases, the authors 
said that doxycycline was a broad-spectrum antibiotic that 
was effective against some of the most common bacterial 
causes of sexually transmitted diseases, such as myco-
plasmas and chlamydia.
A limitation of our study is that there was no control 
group. Another limitation was that, though the improve-
ment did not reach statistical significance, there was a con-
siderable improvement in symptoms among the 5 women 
with persistent infection. We cannot explain this change, 
because there was no placebo group, but a placebo effect 
may be at least partially responsible. To confirm the cau-
sality of mycoplasma infections for OAB symptoms and the 
efficacy of antimicrobial treatment for the symptoms, ran-
domized placebo-controlled trials are needed. Lastly, we 
enrolled patients who had only mild symptoms and no pre-
vious anticholinergic treatment. This may not reflect prac-
tice in real life, in which anticholinergics are the first-line 
treatment for OAB. Therefore, study with patients who 
have persistent OAB symptoms after anticholinergic med-
ication would add more clinically relevant information on 
this subject.
CONCLUSIONS
The prevalence of genitourinary mycoplasma infection was 
high in women with OAB symptoms. After antimicrobial 
treatment, micturition frequency and symptom question-
naires were significantly improved, and the patient per-
ception of treatment benefit and satisfaction were high. 
Diagnostic tests and treatment for genitourinary myco-
plasmas would be beneficial for improving OAB symptoms 
in women before invasive and costly diagnostic tests and 
treatments are considered.
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